1.Sexual dysfunction in patients with chronic renal failure.
Jing GUAN ; Wei-Dong ZHANG ; Guo-Hui PENG ; Jun-Ming FAN
National Journal of Andrology 2003;9(6):454-461
Sexual dysfunction is a highly prevalent problem among patients with chronic renal failure, which affects patients in the quality of life. However, it has not received enough attention. The genesis of sexual dysfunction is multifactorial, including physiological, psychological and organic factors. This review summarized the incidence, main manifestation, evaluation, risk factors and treatments associated with sexual dysfunction in patient of the chronic renal failure.
Female
;
Humans
;
Kidney Failure, Chronic
;
complications
;
physiopathology
;
psychology
;
Male
;
Sexual Dysfunction, Physiological
;
etiology
;
therapy
;
Sexual Dysfunctions, Psychological
;
etiology
;
therapy
2.Copeptin in Hemodialysis Patients with Left Ventricular Dysfunction.
Jae Seok KIM ; Jae Won YANG ; Moon Hee CHAI ; Jun Young LEE ; Hyeoncheol PARK ; Youngsub KIM ; Seung Ok CHOI ; Byoung Geun HAN
Yonsei Medical Journal 2015;56(4):976-980
PURPOSE: Copeptin has been considered as a useful marker for diagnosis and prediction of prognosis in heart diseases. However, copeptin has not been investigated sufficiently in hemodialysis patients. This study aimed to investigate the general features of copeptin in hemodialysis and to examine the usefulness of copeptin in hemodialysis patients with left ventricular dysfunction (LV dysfunction). MATERIALS AND METHODS: This study included 41 patients on regular hemodialysis. Routine laboratory data and peptides such as the N-terminal of the prohormone brain natriuretic peptide and copeptin were measured on the day of hemodialysis. Body fluid volume was estimated by bioimpedance spectroscopy, and the E/Ea ratio was estimated by echocardiography. RESULTS: Copeptin increased to 171.4 pg/mL before hemodialysis. The copeptin had a positive correlation with pre-dialysis body fluid volume (r=0.314; p=0.04). The copeptin level decreased along with body fluid volume and plasma osmolality during hemodialysis. The copeptin increased in the patients with LV dysfunction more than in those with normal LV function (218.7 pg/mL vs. 77.6 pg/mL; p=0.01). Receiver operating characteristic curve analysis showed that copeptin had a diagnostic value in the hemodialysis patients with LV dysfunction (area under curve 0.737; p=0.02) and that the cut-off value was 125.48 pg/mL (sensitivity 0.7, specificity 0.8, positive predictive value 0.9, negative predictive value 0.6). CONCLUSION: Copeptin increases in hemodialysis patients and is higher in patients with LV dysfunction. We believe that copeptin can be a useful marker for the diagnosis of LV dysfunction in hemodialysis patients.
Adult
;
Aged
;
Biomarkers/blood
;
Echocardiography
;
Female
;
Glycopeptides/*blood
;
Humans
;
Kidney Failure, Chronic/*blood/complications/therapy
;
Male
;
Middle Aged
;
Natriuretic Peptide, Brain/blood
;
Predictive Value of Tests
;
Prognosis
;
ROC Curve
;
Renal Dialysis/*adverse effects
;
Sensitivity and Specificity
;
Ventricular Dysfunction, Left/*blood/complications/*physiopathology
3.Recurrent Intraocular Pressure Elevation during Hemodialysis in a Patient with Neovascular Glaucoma.
Won Kyung SONG ; Seung Joo HA ; Ho Yeup YEOM ; Gong Jae SEOUNG ; Young Jae HONG
Korean Journal of Ophthalmology 2006;20(2):109-112
PURPOSE: To report a patient with symptomatic intraocular pressure (IOP) elevation in an eye with neovascular glaucoma (NVG) during hemodialysis. METHODS: Case report. RESULTS: Recurrent episodes of severe ocular pain and elevated IOP in the NVG eye were noted during hemodialysis in a 29-year-old man. The patient was recently diagnosed at our ophthalmology clinic with NVG due to central retinal vein occlusion. IOP was temporarily controlled after the Ahmed valve implantation. However, after the fibrous membrane developed and occluded the tip of the Ahmed valve, IOP elevation during hemodialysis recurred. Further treatments with intravenous mannitol, oral carbonic anhydrase inhibitor, topical antiglaumatic agents and subconjunctival 5-fluorouracil (5-FU) injections all failed to control relapsing pain and IOP elevation. Eventually, evisceration and hydroxyappatite implantation were performed. CONCLUSIONS: Physicians must be alert to the possibility of IOP elevation in glaucomatous eyes during hemodialysis.
Renal Dialysis/*adverse effects
;
Recurrence
;
Male
;
Kidney Failure, Chronic/complications/*therapy
;
Intraocular Pressure/*physiology
;
Humans
;
Glaucoma, Neovascular/complications/*physiopathology/surgery
;
Glaucoma Drainage Implants
;
Follow-Up Studies
;
Filtering Surgery/instrumentation
;
Adult
4.AST-120 Improves Microvascular Endothelial Dysfunction in End-Stage Renal Disease Patients Receiving Hemodialysis.
Jung Hwa RYU ; Mina YU ; Sihna LEE ; Dong Ryeol RYU ; Seung Jung KIM ; Duk Hee KANG ; Kyu Bok CHOI
Yonsei Medical Journal 2016;57(4):942-949
PURPOSE: Endothelial dysfunction (ED) is a pivotal phenomenon in the development of cardiovascular disease (CVD) in patients receiving hemodialysis (HD). Indoxyl sulfate (IS) is a known uremic toxin that induces ED in patients with chronic kidney disease. The aim of this study was to investigate whether AST-120, an absorbent of IS, improves microvascular or macrovascular ED in HD patients. MATERIALS AND METHODS: We conducted a prospective, case-controlled trial. Fourteen patients each were enrolled in respective AST-120 and control groups. The subjects in the AST-120 group were treated with AST-120 (6 g/day) for 6 months. Microvascular function was assessed by laser Doppler flowmetry using iontophoresis of acetylcholine (Ach) and sodium nitroprusside (SNP) at baseline and again at 3 and 6 months. Carotid arterial intima-media thickness (cIMT) and flow-mediated vasodilation were measured at baseline and 6 months. The Wilcoxon rank test was used to compare values before and after AST-120 treatment. RESULTS: Ach-induced iontophoresis (endothelium-dependent response) was dramatically ameliorated at 3 months and 6 months in the AST-120 group. SNP-induced response showed delayed improvement only at 6 months in the AST-120 group. The IS level was decreased at 3 months in the AST-120 group, but remained stable thereafter. cIMT was significantly reduced after AST-120 treatment. No significant complications in patients taking AST-120 were reported. CONCLUSION: AST-120 ameliorated microvascular ED and cIMT in HD patients. A randomized study including a larger population will be required to establish a definitive role of AST-120 as a preventive medication for CVD in HD patients.
Acetylcholine
;
Adult
;
Carbon/*therapeutic use
;
Cardiovascular Diseases/etiology/*prevention & control
;
Carotid Intima-Media Thickness
;
Endothelium, Vascular/*physiopathology
;
Female
;
Humans
;
Iontophoresis
;
Kidney Failure, Chronic/complications/*physiopathology/*therapy
;
Laser-Doppler Flowmetry
;
Male
;
Microcirculation/physiology
;
Middle Aged
;
Nitroprusside
;
Oxides/*therapeutic use
;
Prospective Studies
;
*Renal Dialysis
;
Young Adult